Market accessCompany release

BioLargo's Clyra Medical reports early uptake of FDA-cleared ViaCLYR wound irrigant

🇺🇸 Biolargo, Inc. (BLGO) · Mon 02 Nov 2026

Subsidiary Clyra Medical says ViaCLYR has been used in hundreds of patients since its March 2026 launch and is under evaluation at several US health systems.

BioLargo, Inc. has released a fireside chat video outlining commercial progress at its subsidiary Clyra Medical. The company published it on 2 November 2026, following the SAWC Fall 2026 symposium.

The focus is ViaCLYR, a wound irrigation solution cleared by the US Food and Drug Administration through the 510(k) pathway. Since its launch in March 2026, the product has been used in hundreds of patients, according to the company.

Clyra says it is going through evaluations with several US health systems. It has distribution arrangements with Advanced Solution, Spartan Medical and Al Hikma, with registrations under way in the Middle East.

The company also plans to add a further product line with a partner it has not named. No other details on timing, pricing, sales volumes or clinical outcomes were given in the material available. The 510(k) route allows clearance on the basis of substantial equivalence to a legally marketed predicate device.

What it means for your team

  • Hospital value-analysis and procurement teams are likely to see ViaCLYR in formal evaluation processes at US health systems, though none has been named.
  • Regulatory teams tracking Middle East market entry should note that registrations for ViaCLYR are under way via Al Hikma, with no approval dates disclosed.
  • The usage figure (hundreds of patients) is a company statement, and no clinical or outcomes data accompanied it.
  • An additional product line with an undisclosed partner is planned, but there is no information yet on its regulatory status.

Company's press release (SEC filing): Biolargo, Inc. ↗

Article written by VigiEye from the official source (Biolargo, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →